INTRODUCTION AND OBJECTIVES: Growing evidence has proved obesity one of the confirmed important etiologic indicators for renal cell carcinoma (RCC). CD36 is underpinned to be involved in adipose absorption, but its role in clear cell renal cell carcinoma (ccRCC) remains unclear. This study aimed to investigate the mRNA expression of CD36 in anthropometric measures of adipose tissue and defining its value in predicting METHODS: Real-Time quantitative PCR gene expression analysis was detected from 367 paired ccRCC and adjacent normal tissues. Distributions of categorical clinical-pathological data together with levels of CD36 expression were compared with c2-test in a contingency table. Differential expression of CD36 in normal tissue versus tumor tissues was screened in The Cancer Genome Atlas (TCGA) database. Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were measured by magnetic resonance imaging (MRI) and identified at the level of the umbilicus. Pearson's correlation coefficient was utilized to quantify relations between body mass index (BMI), VAT%, SAT and CD36 expression respectively. Partial likelihood test from univariate and multivariate Cox regression analysis were developed to address the influence of independent factors on progression-free survival (PFS) and overall survival (OS). The Kaplan-Meier method and log-rank test were performed to assess the survival benifits between discrete levels.Set Enrichment Analysis (GSEA) was performed to select related genes and pathways from The Cancer Genome Atlas (TCGA) database.
RESULTS: In the current study, we demonstrated that CD36 mRNA was highly expressed in ccRCC compared with normal tissues. -0.296, p[0.002) . Meanwhile, median PFS was 60 months and OS was 99 months. Furthermore, ccRCC patients with elevated CD36 expression held shorter PFS and OS, with hazard ratios (HR; 95% confidence interval (CI)) of 4. 873 (3.300-7.196, p<0.001) and 4.610 (2.956-7.189, p<0.001) . In 104 cases whose MRI scans were available, VAT was significantly correlated with poor PFS and OS, with hazard ratios of 2.556 (1.036-6.310, p<0.042) and 3.291 (1.034-10.477, p<0.044). A total of 100 significant genes were obtained from GSEA, and CD36 was found involved in the most significant pathways including fatty acid metabolism, UV response, angiogenesis and transforming growth factor beta (TGF-b) signaling pathways.
CONCLUSIONS: In conclusion, our study first reveal that elevated CD36 mRNA expression is positively correlated to distribution of abdominal adipose, particularly VAT%, which, in addition, notably predicts poor prognosis in ccRCC patients.
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This work is supported by Grants from the National Natural Science Foundation of China (Nos. 81202004, 81802525, 81722021, 81771627, 81471454) METHODS: All patients which were collected from five institutions were diagnosed by immunohistochemistry staining of TFE3 and fluorescence in situ hybridization between January 2007 and September 2018. Their clinicopathologic features, treatment methods and prognosis were retrospectively reviewed. Kaplan-Meier methods were performed to estimate survival, and Cox proportional hazards model was used to evaluate the predictive role of the factors.
RESULTS: In total, 72 cases of Xp11.2 tRCC were identified. Of the 72 enrolled patients, 31 (43.1%) were female and 41 (56.9%) were male, who aged from 2 to 72 years. Gross hematuria and abdominal mass were frequent symptoms. The mean tumor size was 5.7AE2.6 centimeters. Among the 48 (66.7%) patients who were classified as stage I/II, 19 (39.6%) cases received nephron-sparing surgery (NSS) and 29 (60.4%) cases received radical nephrectomy (RN). The other 24 (33.3%) patients who were classified as stage III/IV received RN. Vena caval tumor thrombectomy was simultaneously performed on 8 (11.1%) patients who had vena cava tumor thrombosis. After operation, 31 of 48 (64.6%) patients in stage I/II received adjuvant immunotherapy (Interleukin-2/Interferon-a), and 23 of 24 (95.8%) patients in stage III/IV received adjuvant VEGF-targeted therapy (Sorafenib/Sunitinib). Threeyear overall survival rate (OS) and progression-free survival rate (PFS) of patients in stage III/IV were 51.1% and 57.4%. which contrast to patients in stage I/II were 97.2% and 87.4%, respectively. There was no significance between NSS and RN for patients in stage T1a.On univariate analysis, tumor size, adjuvant treatment, pathological stage and vena cava tumor thrombosis showed association with both PFS and OS but lymph node metastasis is only related to OS (all P<0.05). Multivariate analysis indicated that pathological stage (P[0.009) and vena cava tumor thrombosis (P[0.006) were independent prognostic factors of PFS, and that vena cava tumor thrombosis (P[0.015) and lymph node metastasis (P[0.002) showed independent prognostic significance of OS. CONCLUSIONS: Xp11.2 tRCC mainly occurs in young females. NSS can be performed for cases in stage T1a, otherwise, RN should be considered. The occurrence of vein tumor thrombosis and advance stage indicated poor prognosis.
Source of Funding: National Natural Science Foundation of China (81572512) MP19-06 RENAL NEPHROMETRY SCORE CORRELATED WITH TUMOR PROLIFERATIVE ACTIVITY OF T1 CLEAR CELL RENAL CELL CARCINOMA Hiroshi Kikuchi*, Takashige Abe, Ryuji Matsumoto, Jun Furumido, Haruka Miyata, Takahiro Osawa, Sachiyo Murai, Nobuo Shinohara, Sapporo, Japan INTRODUCTION AND OBJECTIVES: Previously, several researchers reported that a high RENAL nephrometry score (RNS) was associated with an unfavorable pathology in renal cell carcinoma (RCC) patients. Our group also reported that RNS was associated with the annual tumor growth rate on linear regression analysis of 47 renal tumors with at least a 12-month follow-up duration (Matsumoto et al., IJU 2014) . These observations suggest that anatomic features of RCCs are associated with the tumor proliferative ability or malignant potential. In the present study, in order to gain further insights into the association
